Chiesi Farmaceutici S.p.a.

Brian Meakin

Gaetano Brambilla

David Andrew Lewis

David Ganderton

Paolo Ventura

Raffaella Garzia

Alessandra Ferraris

An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using a small amount of mineral acid and a suitable can having part or all of its internal metallic surfaces made of stainless steel, anodized aluminium or lined with an inert organic coating.

Stable pharmaceutical solution formulations for pressurized metered dose inhalers

In a solution composition for use in an aerosol inhaler which comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility compound the use of a mixture of HFA 134 and HFA 227 allows to modulate the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler to target specific regions of the respiratory tract. Moreover the fine particle dose (FPD) of the active ingredient in the composition increases by reducing the metering chamber volume.

Pharmaceutical aerosol composition containing HFA 227 and HFA 134a

Growing community of inventors

Batty, United Kingdom

Brian Meakin